Nuvectis Pharma (NASDAQ:NVCT) CEO Acquires $28,600.00 in Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur purchased 5,000 shares of Nuvectis Pharma stock in a transaction that occurred on Wednesday, November 5th. The stock was acquired at an average cost of $5.72 per share, with a total value of $28,600.00. Following the transaction, the chief executive officer owned 3,525,924 shares in the company, valued at $20,168,285.28. This trade represents a 0.14% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Nuvectis Pharma Price Performance

NVCT opened at $5.65 on Thursday. The company has a market capitalization of $143.85 million, a price-to-earnings ratio of -4.12 and a beta of -0.28. The firm’s fifty day moving average price is $6.23 and its two-hundred day moving average price is $7.55. Nuvectis Pharma, Inc. has a 1 year low of $4.44 and a 1 year high of $11.80.

Nuvectis Pharma (NASDAQ:NVCT) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.20). As a group, equities analysts anticipate that Nuvectis Pharma, Inc. will post -1.01 EPS for the current year.

Institutional Investors Weigh In On Nuvectis Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NVCT. Iridian Asset Management LLC CT bought a new stake in shares of Nuvectis Pharma during the first quarter valued at about $2,481,000. Austin Wealth Management LLC bought a new position in shares of Nuvectis Pharma in the first quarter worth approximately $393,000. OMERS ADMINISTRATION Corp bought a new position in shares of Nuvectis Pharma in the first quarter worth approximately $321,000. Goldman Sachs Group Inc. bought a new position in Nuvectis Pharma during the first quarter valued at approximately $446,000. Finally, Jane Street Group LLC bought a new position in Nuvectis Pharma during the first quarter valued at approximately $413,000. 96.77% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on NVCT. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nuvectis Pharma in a report on Wednesday, October 8th. HC Wainwright cut their price target on shares of Nuvectis Pharma from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Monday, August 4th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $15.33.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.